Jonathan Weiss / Shutterstock.com
18 February 2020Big PharmaRory O'Neill
Eli Lilly claims another victory in Taltz patent battle
The English High Court has invalidated key claims of a patent owned by Roche subsidiary Genentech, following a lawsuit filed by US rival Eli Lilly.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
1 March 2019 The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.
Editor's picks
Editor's picks
Big Pharma
1 March 2019 The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.
Big Pharma
1 March 2019 The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.